Hippo通路在原发性肝癌发生发展中的作用

洪莹晖; 王纯; 叶明亮; 罗杰; 刘佳良; 任超; 蓝偲瑜; 赵秋; 常莹

doi:10.3969/j.issn.1001-5256.2020.05.050

Hippo通路在原发性肝癌发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2020.05.050

武汉大学中南医院消化内科，湖北省肠病医学临床研究中心肠病湖北省重点实验室

基金项目:

国家自然科学基金项目（81670554）；湖北省自然科学基金项目（2017CFA068）；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 743
- HTML全文浏览量: 49
- PDF下载量: 122
- 被引次数: 0
出版历程
- 出版日期: 2020-05-20

Role of the Hippo signaling pathway in the development and progression of primary liver cancer

Hubei Key Laboratory of Intestinal and Colorectal Diseases, Hubei Clinical Center of Intestinal and Colorectal Diseases, Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Research funding:

摘要

摘要:
原发性肝癌在全球范围内发病率持续上升,发病年龄趋于年轻化,并且总体预后不良。Hippo通路作为最经典的感知细胞极性和密度、机械信号转导并促进细胞增殖、器官发育的调节器,能够促进包括原发性肝癌在内多种癌症的发生发展。YAP作为Hippo通路的经典核效应器在原发性肝癌中显著上调,并且促进原发性肝癌耐药的发生。原发性肝癌中Hippo信号通路的失调与肝癌的发生发展相联系,Hippo信号通路作为原发性肝癌发生的早期事件,影响原发性肝癌耐药的发生机制,这对于探索新的原发性肝癌临床治疗策略具有重要意义。
- 肝肿瘤 /
- 信号传导 /
- Hippo通路
Abstract:
The incidence rate of primary liver cancer continues to increase around the world, with a younger age of onset and poorer prognosis. As the most classic regulator of cell polarity and density, mechanical signal transduction, cell proliferation, and organ development, the Hippo pathway can promote the development and progression of various cancers including primary liver cancer. YAP, a classic nuclear effector of the Hippo pathway, is significantly upregulated in primary liver cancer and promotes the development of drug resistance. This article aims to investigate the association of the dysregulation of the Hippo signaling pathway with the development and progression of primary liver cancer and analyzes the mechanism of action of the Hippo signaling pathway in the drug resistance of primary liver cancer as an early event of the development of primary liver cancer, which is of great significance for exploring new treatment strategies for primary liver cancer.
- liver neoplasms /
- signal transduction /
- Hippo pathway

HTML全文

参考文献(40)

[1] RAWLA P, SUNKARA T, MURALIDHARAN P, et al. Update in global trends and aetiology of hepatocellular carcinoma[J].Contemp Oncol(Pozn), 2018, 22(3):141-150.

[2] WANG Y, DONG Q, ZHANG Q, et al. Overexpression of yesassociated protein contributes to progression and poor prognosis of non-small-cell lung cancer[J]. Cancer Sci, 2010, 101(5):1279-1285.

[3] XIA Y, CHANG T, WANG Y, et al. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients[J]. PLoS One, 2014, 9(3):e91770.

[4] YANG Y, WU QJ, XIE L, et al. Prospective cohort studies of association between family history of liver cancer and risk of liver cancer[J]. Int J Cancer, 2014, 135(7):1605-1614.

[5] OTA M, SASAKI H. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling[J]. Development, 2008, 135(24):4059-4069.

[6] ZHAO B, WEI X, LI W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control[J]. Genes Dev, 2007, 21(21):2747-2761.

[7] HALDER G, JOHNSON RL. Hippo signaling:Growth control and beyond[J]. Development, 2011, 138(1):9-22.

[8] ZANCONATO F, BATTILANA G, CORDENONSI M, et al. YAP/TAZ as therapeutic targets in cancer[J]. Curr Opin Pharmacol,2016, 29:26-33.

[9] ZHU C, LI L, ZHAO B. The regulation and function of YAP transcription co-activator[J]. Acta Biochim Biophys Sin(Shanghai), 2015, 47(1):16-28.

[10] MACIAS MJ, HYVÖNEN M, BARALDI E, et al. Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide[J]. Nature, 1996, 382(6592):646-649.

[11] YAGI R, CHEN LF, SHIGESADA K, et al. A WW domaincontaining yes-associated protein(YAP)is a novel transcriptional co-activator[J]. EMBO J, 1999, 18(9):2551-2562.

[12] OKA T, REMUE E, MEERSCHAERT K, et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling[J].Biochem J, 2010, 432(3):461-472.

[13] KOWALIK MA, SALIBA C, PIBIRI M, et al. Yes-associated protein regulation of adapative liver enlargement and hepatocellular carcinoma development in mice[J]. Hepatology,2011, 53(6):2086-2096.

[14] MOON S, KIM W, KIM S, et al. Phosphorylation by NLK inhibits YAP-14-3-3-interactions and induces its nuclear localization[J]. EMBO Rep, 2017, 18(1):61-71.

[15] LIU CY, ZHA ZY, ZHOU X, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase[J]. J Biol Chem, 2010, 285(48):37159-37169.

[16] HANSEN CG, MOROISHI T, GUAN KL. YAP and TAZ:A nexus for Hippo signaling and beyond[J]. Trends Cell Biol,2015, 25(9):499-513.

[17] MOROISHI T, HANSEN CG, GUAN KL. The emerging roles of YAP and TAZ in cancer[J]. Nat Rev Cancer, 2015, 15(2):73-79.

[18] MOYA IM, HALDER G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine[J]. Nat Rev Mol Cell Biol, 2019, 20(4):211-226.

[19] GUO LW, SHAO GL, LUO J, et al. YAP regulates the proliferation and modifies the sensitivity to sorafenib in hepatocellular carcinoma cells[J]. Chin J Oncol, 2018, 40(11):818-823.(in Chinese）郭立文，邵国良，罗君，等．YAP调控肝癌细胞增殖活性及对索拉非尼敏感性的影响[J]．中华肿瘤杂志，2018, 40(11):818-823.

[20] BÖTTCHER K, PINZANI M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents[J]. Adv Drug Deliv Rev, 2017, 121:3-8.

[21] ZAGHARI Z, AZIZIAN J. Synthesis of novelα-amidino carboxylic acids and their use as H-Bond catalysts in strecker reaction[J]. Comb Chem High Throughput Screen, 2018, 21(8):609-614.

[22] de OLIVEIRA DA SILVA B, RAMOS LF, MORAES K. Molecular interplays in hepatic stellate cells:Apoptosis, senescence,and phenotype reversion as cellular connections that modulate liver fibrosis[J]. Cell Biol Int, 2017, 41(9):946-959.

[23] DUPONT S, MORSUT L, ARAGONA M, et al. Role of YAP/TAZ in mechanotransduction[J]. Nature, 2011, 474(7350):179-183.

[24] MANNAERTS I, LEITE SB, VERHULST S, et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation[J]. J Hepatol, 2015, 63(3):679-688.

[25] KIM W, KHAN SK, GVOZDENOVIC-JEREMIC J, et al. Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis[J]. J Clin Invest, 2017,127(1):137-152.

[26] MOON H, CHO K, SHIN S, et al. High risk of hepatocellular carcinoma development in fibrotic liver:Role of the HippoYAP/TAZ signaling pathway[J]. Int J Mol Sci, 2019, 20(3):581-583.

[27] LIN TH, SHAO YY, CHAN SY, et al. High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib[J]. Clin Cancer Res,2015, 21(16):3678-3684.

[28] FERRIGNO O, LALLEMAND F, VERRECCHIA F, et al. Yesassociated protein(YAP65)interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling[J]. Oncogene, 2002, 21(32):4879-4884.

[29] LIU F, LAGARES D, CHOI KM, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis[J]. Am J Physiol Lung Cel Mol Physiol, 2015, 308(4):L344-357.

[30] VARELAS X, SAMAVARCHI-TEHRANI P, NARIMATSU M, et al.The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway[J]. Dev Cell,2010, 19(6):831-844.

[31] de LA COSTE A, ROMAGNOLO B, BILLUART P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas[J]. Proc Natl Acad Sci U S A, 1998, 95(15):8847-8851.

[32] BARTEL DP. MicroRNAs:Target recognition and regulatory functions[J]. Cell, 2009, 136(2):215-233.

[33] LIU AM, POON RT, LUK JM. MicroRNA-375 targets Hipposignaling effector YAP in liver cancer and inhibits tumor properties[J]. Biochem Biophys Res Commun, 2010, 394(3):623-627.

[34] HAN LL, YIN XR, ZHANG SQ. miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2[J]. Int J Oncol, 2018, 53(6):2433-2444.

[35] RUAN T, HE X, YU J, et al. MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma[J]. Oncol Lett, 2016, 11(4):2941-2945.

[36] LIU P, ZHANG H, LIANG X, et al. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma[J]. Oncotarget, 2015, 6(30):29048-29059.

[37] WU H, ZHANG W, WU Z, et al. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocel ular carcinoma[J]. Cel Death Dis, 2019, 10(2):48.

[38] KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173.

[39] CUI YL. Targeted therapy for hepatocellular carcinoma[J].Chin J Dig Surg, 2018, 17(5):445-451.(in Chinese）崔云龙．肝癌的靶向治疗[J]．中华消化外科杂志，2018, 17(5):445-451.

[40] GAO J, RONG Y, HUANG Y, et al. Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP[J]. J Cell Physiol, 2019,234(3):2639-2648.

施引文献

资源附件(0)

访问统计